A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine.
about
Antiviral drug resistance: mechanisms and clinical implicationsProteins ZNF198 and SUZ12 are down-regulated in hepatitis B virus (HBV) X protein-mediated hepatocyte transformation and in HBV replicationA comparison of 48-week treatment efficacy between clevudine and entecavir in treatment-naïve patients with chronic hepatitis B.Emerging drugs for hepatitis B.PLK1 and HOTAIR Accelerate Proteasomal Degradation of SUZ12 and ZNF198 during Hepatitis B Virus-Induced Liver CarcinogenesisPredictive factors of lamivudine treatment success in an hepatitis B virus-infected pediatric cohort: a 10-year study.Characterization of a new sensitive PCR assay for quantification of viral DNA isolated from patients with hepatitis B virus infectionsTesting for hepatitis B infection in prospective chemotherapy patients: a retrospective studyEpidemiological, virological and clinical characteristics of HBV infection in 223 HIV co-infected patients: a French multi-centre collaborative study.Antiviral-resistant hepatitis B virus: can we prevent this monster from growing?Effects of two novel nucleoside analogues on different hepatitis B virus promoters.Pathobiology of HBV mutants and clinical impact for treatment monitoring.Monotherapy versus combination therapy for the treatment of chronic hepatitis B.Gene signatures in hepatocellular carcinoma (HCC).Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance.Management of antiviral drug resistance in chronic hepatitis BDevelopment of a novel mouse model to evaluate drug candidates against hepatitis B virus.In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.Design, Synthesis, and Evaluation of Tetrahydropyrrolo[1,2-c]pyrimidines as Capsid Assembly Inhibitors for HBV Treatment.Lamivudine monotherapy in chronic hepatitis B patients from the Indian subcontinent: antiviral resistance mutations and predictive factors of treatment response.Subset of Suz12/PRC2 target genes is activated during hepatitis B virus replication and liver carcinogenesis associated with HBV X protein.A case for treating high hepatitis B DNA levels before starting HIV therapy.An efficient synthesis of enantiopure (R)-heteroarylpyrimidine analogs.Differential roles of serum hepatitis B virus DNA and hepatitis B surface antigen level in predicting virological breakthrough in patients receiving lamivudine therapy.Successful lamivudine monotherapy in an elderly patient suffering from HBV-related decompensated cirrhosis associated with widespread leukocytoclastic vasculitis.
P2860
Q28282376-2FB2A919-2A1E-471E-B342-0008BFCC4F12Q33867835-5399EA05-4027-403A-8EBC-FA12C2606F76Q34959568-7082D9FA-C776-4AA2-A526-551297838618Q35359369-29EF4437-527E-446E-8571-69952DF05249Q35674884-0E58BA75-3208-4052-B5CD-7FAC12A2AED3Q36091371-61A95CB9-F84E-4EE0-9F2E-9D409AAB9AEBQ36314573-0694C08E-74E6-41E9-A57A-3D6BB53FCE51Q36616847-08359307-32D0-4333-9F29-2618672D180CQ36698116-125AEAF1-63D1-4430-BAF0-350233EEC1B3Q36980718-5EB87377-E30B-4F04-A7DD-D5A5C5A0DC87Q37240363-6483CEB2-E367-466D-94A9-5A5E7F22F909Q37432098-33246BE8-E2E3-4AC1-87C5-7DA0C34C76DFQ37620354-AC6D03B3-C6E5-4215-B57D-D256F9D575DAQ37790070-16418FD7-00C8-4300-AE2E-BD86629C4546Q38071396-00EDEDBB-F328-4C99-B23E-080224453DC2Q38247981-1A6F2050-2FA2-41BD-A2A2-95FA545BAF02Q40073982-30BABB5D-E3E3-4D2E-B35F-C722CFFA13EEQ40157026-DBF500D5-694F-43A4-9EF6-5D979E10815FQ41930281-1AE078F0-D695-4BA8-9F4D-AF5622E2A3C7Q42270061-06DE1481-166E-4D4B-BE9A-E62BD5319094Q42272234-0DEAA058-AC38-47C6-91F8-A1AA4DD7E25AQ42425880-F9AAE5CE-5953-4C1F-9E04-F6C840B91856Q43692897-3E060242-4176-4175-A8CC-374DF8A616D0Q45350931-3D2C69C6-2A48-4E0E-9FF3-8C93D1E7EFFAQ45978196-A3BF6362-8F3C-4DAE-9203-16057547BBAB
P2860
A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
A prospective study of the evo ...... tis B treated with lamivudine.
@ast
A prospective study of the evo ...... tis B treated with lamivudine.
@en
type
label
A prospective study of the evo ...... tis B treated with lamivudine.
@ast
A prospective study of the evo ...... tis B treated with lamivudine.
@en
prefLabel
A prospective study of the evo ...... tis B treated with lamivudine.
@ast
A prospective study of the evo ...... tis B treated with lamivudine.
@en
P2093
P2860
P1476
A prospective study of the evo ...... tis B treated with lamivudine.
@en
P2093
A El Hasnaoui
Lamivir Study Group
P2860
P304
P356
10.1111/J.1365-2893.2005.00712.X
P577
2006-04-01T00:00:00Z